TED Member States· European UniontenderOpen · 20 Oct 2026
Immunosuppressive - TNF alpha inhibitor II.
Institut klinické a experimentální medicíny
Deadline 20 Oct 2026Deadline20 Oct 2026
Estimated valueCZK 72,122,000
CPV category33652300
Published18 Sep 2026
Reference646821-2026
Notice summary
The subject of the public procurement is the supply of medicinal products for parenteral administration from the group of TNF alpha inhibitors (infliximab and adalimumab) for the treatment of patients in approved indications according to the SmPC valid at the time of submission of the offer.
Is this worth bidding on?
Tender Radar scores every tender against your company profile, surfaces the matching services, and flags the ones worth your time — across Europe and beyond. Sign in to see the relevance match and full AI analysis for this opportunity.